Top Abstracts with Expert Perspective: Acute Leukaemias and Transplantation
Tracks
-
| Monday, April 20, 2026 |
| 3:25 PM - 4:55 PM |
| Hall 3A, Upper Level |
Speaker
Dr. Pramila Krishnamurthy
Consultant Haematologist
King's College Hospital, London
Session Chair
Dr. Razia Akhtar
Clinical Director
Merck & Co., Inc. (rahway, Nj)
Updated Phase 1b/2 Results: MK-1045 in Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
3:25 PM - 3:40 PM
Dr Eleni Tholouli
Consultant Haematologist,
Manchester Royal Infirmary, Manchester, UK
Three-year Outcomes with Obecabtagene autoleucel in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (R/R B-ALL)
3:40 PM - 3:55 PM
Dr Graham McIlroy
Clinical Lecturer
University of Birmingham
Thiotepa based conditioning reduces relapse without improving survival in patients allografted for acute myeloid leukaemia
3:55 PM - 4:10 PM
Mr Yi Xia
Ph.d. Candidate
Peking University People's Hospital
RUNX1–RUNX1T1 trancript kinetics and co-mutations impact post-transplant outcomes in t(8;21) acute myeloid leukemia
4:10 PM - 4:25 PM
Dr Jennifer Vidler
Haematology Specialist Registrar
King's College Hospital NHS Foundation Trust
Deep Immunophenotyping Identifies Differential Immune Profiles in Recipients of Donor Lymphocyte Infusions
4:25 PM - 4:40 PM
Dr Eleni Tholouli
Consultant Haematologist,
Manchester Royal Infirmary, Manchester, UK
Obecabtagene autoleucel Persistence at Month 3 Predicts Outcomes in Adult Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
4:40 PM - 4:55 PM
